<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39282763</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0496</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Pediatric pulmonology</Title><ISOAbbreviation>Pediatr Pulmonol</ISOAbbreviation></Journal><ArticleTitle>Prevalence of symptoms of post-COVID-19 condition (long COVID) in children hospitalized with COVID-19: A systematic review of observational studies.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ppul.27257</ELocationID><Abstract><AbstractText>This systematic review aimed to investigate the prevalence of symptoms of post-COVID-19 condition (long COVID), in children hospitalized with COVID-19. We searched PUBMED and EMBASE on 15 March, 2023, using search strategy: "long COVID" OR "post-COVID-19" OR "postacute COVID-19" OR "long-term COVID" OR "COVID-19 sequelae" OR "persistent COVID-19" OR "chronic COVID-19". We included observational studies (case-control, cross-sectional, cohort, or case series) that investigated symptoms of post-COVID-19 condition (long COVID) in children (&lt;18 years) admitted with COVID-19. We used the WHO case definition of post-COVID-19 condition. Long COVID was defined as persistence of otherwise unexplained symptoms for at least three months after SARS-CoV-2 infection. We used the command "metaprop" to perform random-effects meta-analysis. Eleven studies involving 2279 patients were included. In the period between &#x2265;3 months and &lt;12 months after acute COVID-19, the most frequent symptom was exercise intolerance with a pooled prevalence of 29% (95% CI: 7%-57%, I<sup>2</sup>&#x2009;=&#x2009;95%), followed by nonspecific respiratory symptoms (12%, 95% CI: 0%-48%, I<sup>2</sup>&#x2009;=&#x2009;0%), psychological disorders (10%, 95% CI: 1%-25%, I<sup>2</sup>&#x2009;=&#x2009;97%), and nonspecific gastrointestinal symptoms (10%, 95% CI: 0%-37%, I<sup>2</sup>&#x2009;=&#x2009;99%). In the period &#x2265;12 months after the initial infection, the pooled prevalence of post COVID symptoms was lower, with 6% (95% CI: 2%-10%, I<sup>2</sup>&#x2009;=&#x2009;83%) for exercise intolerance and 3% (95% CI: 0%-8%, I<sup>2</sup>&#x2009;=&#x2009;89%) for fatigue. In conclusion, symptoms of post-COVID condition (long COVID) in hospitalized children affect multiple organ systems, with higher prevalence in the period up to 12 months after the acute phase of COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Ma&#xed;ra Machado da</ForeName><Initials>MMD</Initials><Identifier Source="ORCID">0009-0000-7300-2400</Identifier><AffiliationInfo><Affiliation>Federal University of Rio Grande, Rio Grande-RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benites</LastName><ForeName>Maryellen Nepomuceno</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0009-0001-8583-7883</Identifier><AffiliationInfo><Affiliation>Federal University of Rio Grande, Rio Grande-RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Yasmin Marques</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Federal University of Rio Grande, Rio Grande-RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>Paulo Victor</ForeName><Initials>PV</Initials><Identifier Source="ORCID">0009-0004-9631-8052</Identifier><AffiliationInfo><Affiliation>Federal University of Rio Grande, Rio Grande-RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linjie</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5150-5840</Identifier><AffiliationInfo><Affiliation>Federal University of Rio Grande, Rio Grande-RS, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Pulmonol</MedlineTA><NlmUniqueID>8510590</NlmUniqueID><ISSNLinking>1099-0496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">meta&#x2010;analysis</Keyword><Keyword MajorTopicYN="N">post&#x2010;COVID&#x2010;19 condition</Keyword><Keyword MajorTopicYN="N">symptoms</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39282763</ArticleId><ArticleId IdType="doi">10.1002/ppul.27257</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zimmermann P, Curtis N. Why is COVID&#x2010;19 less severe in children? A review of the proposed mechanisms underlying the age&#x2010;related difference in severity of SARS&#x2010;CoV&#x2010;2 infections. Arch Dis Child. 2021;106:429&#x2010;439.</Citation></Reference><Reference><Citation>Pierce CA, Herold KC, Herold BC, et al. COVID&#x2010;19 and children. Science (New York, N.Y.). 2022;377:1144&#x2010;1149.</Citation></Reference><Reference><Citation>Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID&#x2010;19: a systematic review. Eur J Pediatr. 2021;180:2019&#x2010;2034.</Citation></Reference><Reference><Citation>Sterky E, Olsson&#x2010;&#xc5;kefeldt S, Hertting O, et al. Persistent symptoms in Swedish children after hospitalisation due to COVID&#x2010;19. Acta Paediatr (Stockholm). 2021;110:2578&#x2010;2580.</Citation></Reference><Reference><Citation>Funk AL, Kuppermann N, Florin TA, et al. Post&#x2010;COVID&#x2010;19 conditions among children 90 days after SARS&#x2010;CoV&#x2010;2 infection. JAMA Network Open. 2022;5:e2223253.</Citation></Reference><Reference><Citation>Doshi JA, Sheils NE, Buresh J, et al. SARS&#x2010;CoV&#x2010;2 sequelae and postdischarge health care visits over 5 months follow&#x2010;up among children hospitalized for COVID&#x2010;19 or MIS&#x2010;C. Pediatr Infect Dis J. 2022;41:e513&#x2010;e516.</Citation></Reference><Reference><Citation>Bogus&#x142;awski S, Strzelak A, Gajko K, et al. The outcomes of COVID&#x2010;19 pneumonia in children&#x2010;clinical, radiographic, and pulmonary function assessment. Pediatr Pulmonol. 2023;58:1042&#x2010;1050.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post&#x2010;COVID&#x2010;19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2010;e107.</Citation></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta&#x2010;analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.</Citation></Reference><Reference><Citation>Stephenson T, Allin B, Nugawela MD, et al. Long COVID (post&#x2010;COVID&#x2010;19 condition) in children: a modified Delphi process. Arch Dis Child. 2022;107:674&#x2010;680.</Citation></Reference><Reference><Citation>National Institutes of Health. Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 6 July 2023.</Citation></Reference><Reference><Citation>Asadi&#x2010;Pooya AA, Nemati H, Shahisavandi M, et al. Long COVID in children and adolescents. World Journal of Pediatrics. 2021;17:495&#x2010;499.</Citation></Reference><Reference><Citation>Asadi&#x2010;Pooya AA, Nemati M, Nemati H. &#x2018;Long COVID&#x2019;: symptom persistence in children hospitalised for COVID&#x2010;19. J Paediatr Child Health. 2022;58:1836&#x2010;1840.</Citation></Reference><Reference><Citation>Balderas LMDCJ, Fern&#xe1;ndez AN, Garza SAD, et al. Long COVID in children and adolescents: COVID&#x2010;19 follow&#x2010;up results in third&#x2010;level pediatric hospital. Front Pediatr. 2023;11:1016394.</Citation></Reference><Reference><Citation>Demirbu&#x11f;a A, Han&#xe7;erli T&#xf6;r&#xfc;n S, Kaba &#xd6;, et al. COVID&#x2010;19 nedeniyle hastanede yatan &#xe7;ocuk hastalarda uzun d&#xf6;nem etkilerin ve uzam&#x131;&#x15f; COVID s&#x131;kl&#x131;&#x11f;&#x131;n&#x131;n de&#x11f;erlendirilmesi. Mikrobiyol Nul. 2023;57:60&#x2010;70.</Citation></Reference><Reference><Citation>Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for post&#x2010;COVID&#x2010;19 condition in previously hospitalised children using the ISARIC global follow&#x2010;up protocol: a prospective cohort study. Eur Respir J. 2022;59:2101341.</Citation></Reference><Reference><Citation>Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and risk factors of post&#x2010;COVID&#x2010;19 condition in adults and children at 6 and 12&#x2009;months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med. 2022;20:244.</Citation></Reference><Reference><Citation>Penner J, Abdel&#x2010;Mannan O, Grant K, et al. 6&#x2010;month multidisciplinary follow&#x2010;up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS&#x2010;TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health. 2021;5:473&#x2010;482.</Citation></Reference><Reference><Citation>Zheng YB, Zeng N, Yuan K, et al. Prevalence and risk factor for long COVID in children and adolescents: a meta&#x2010;analysis and systematic review. J Infect Public Health. 2023;16:660&#x2010;672.</Citation></Reference><Reference><Citation>Behnood SA, Shafran R, Bennett SD, et al. Persistent symptoms following SARS&#x2010;CoV&#x2010;2 infection amongst children and young people: a meta&#x2010;analysis of controlled and uncontrolled studies. J Infect. 2022;84:158&#x2010;170.</Citation></Reference><Reference><Citation>Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr. 2022;181:3995&#x2010;4009.</Citation></Reference><Reference><Citation>Lopez&#x2010;Leon S, Wegman&#x2010;Ostrosky T, Ayuzo Del Valle NC, et al. Long&#x2010;COVID in children and adolescents: a systematic review and meta&#x2010;analyses. Sci Rep. 2022;12:9950.</Citation></Reference><Reference><Citation>Castanares&#x2010;Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473&#x2010;1487.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2010;146.</Citation></Reference><Reference><Citation>Delogu AB, Aliberti C, Birritella L, et al. Autonomic cardiac function in children and adolescents with long COVID: a case&#x2011;controlled study. Eur J Pediatr. 2024;183:2375&#x2010;2382.</Citation></Reference><Reference><Citation>Buonsenso D, Valentini P, De Rose C, et al. Recovering or persisting: the immunopathological features of SARS&#x2010;CoV&#x2010;2 infection in children. J Clin Med. 2022;11:4363.</Citation></Reference><Reference><Citation>Buonsenso D, Martino L, Morello R, Mariani F, Fearnley K, Valentini P. Viral persistence in children infected with SARS&#x2010;CoV&#x2010;2: current evidence and future research strategies. The Lancet Microbe. 2023;4:e745&#x2010;e756.</Citation></Reference><Reference><Citation>Cocciolillo F, Di Giuda D, Morello R, De Rose C, Valentini P, Buonsenso D. Orbito&#x2010;frontal cortex hypometabolism in children with post&#x2010;COVID condition (Long COVID): a preliminary experience. Pediatr Infect Dis J. 2022;41:663&#x2010;665.</Citation></Reference><Reference><Citation>Pizzuto DA, Buonsenso D, Morello R, et al. Lung perfusion assessment in children with long&#x2010;COVID: a pilot study. Pediatr Pulmonol. 2023;58:2059&#x2010;2067.</Citation></Reference><Reference><Citation>Buonsenso D, Munblit D, Pazukhina E, et al. Post&#x2010;COVID condition in adults and children living in the same household in Italy: a prospective cohort study using the ISARIC global follow&#x2010;up protocol. Front Pediatr. 2022;10:834875.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;De&#x2010;Las&#x2010;Pe&#xf1;as C, Palacios&#x2010;Ce&#xf1;a D, G&#xf3;mez&#x2010;Mayordomo V, et al. Prevalence of post&#x2010;COVID&#x2010;19 symptoms in hospitalized and non&#x2010;hospitalized COVID&#x2010;19 survivors: a systematic review and meta&#x2010;analysis. Eur J Intern Med. 2021;92:55&#x2010;70.</Citation></Reference><Reference><Citation>Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS&#x2010;CoV&#x2010;2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID&#x2010;19 risk factors. Allergy. 2020;75:2829&#x2010;2845.</Citation></Reference><Reference><Citation>Migliavaca CB, Stein C, Colpani V, et al. Meta&#x2010;analysis of prevalence: I2 statistic and how to deal with heterogeneity. Res Synth Methods. 2022;13:363&#x2010;367.</Citation></Reference><Reference><Citation>Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta&#x2010;analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21:189.</Citation></Reference><Reference><Citation>Rao S, Lee GM, Razzaghi H, et al. Clinical features and burden of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection in children and adolescents. JAMA Pediatrics. 2022;176:1000&#x2010;1009.</Citation></Reference><Reference><Citation>Buonsenso D, Pazukhina E, Gentili C, et al. The prevalence, characteristics and risk factors of persistent symptoms in non&#x2010;hospitalized and hospitalized children with SARS&#x2010;CoV&#x2010;2 infection followed&#x2010;up for up to 12 months: a prospective, cohort study in Rome, Italy. J Clin Med. 2022;11:6772.</Citation></Reference><Reference><Citation>Morello R, Mariani F, Mastrantoni L, et al. Risk factors for post&#x2010;COVID&#x2010;19 condition (long Covid) in children: a prospective cohort study. EClinicalMedicine. 2023;59:101961.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>